Table 3 Phase 3 trials of tumor necrosis factor (TNF) inhibitors in nonradiographic spondyloarthritis and ankylosing spondylitis
From: Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance
Trial | TNF inhibitor | Dose | Primary endpoint | Comparator | Results |
|---|---|---|---|---|---|
nr-axSpA Trials | |||||
ABILITY-1 [27] | Adalimumab | 40 mg q 2 weeks | ASAS40 response at week 12 | Placebo | ASAS20: 52% vs. 41% ASAS40: 36% vs. 15% |
RAPID-axSpA (nr-axSpA subset) [19] | Certolizumab pegol | 400 mg q 4 weeks | ASAS20 response at week 12 | Placebo | ASAS20: 63% vs. 40% ASAS40: 47% vs. 16% |
EMBARK [51] | Etanercept | 50 mg q week | ASAS40 response at week 12 | Placebo | ASAS20: 52% vs. 36% ASAS40: 33% vs. 15% |
GO-AHEAD [26] | Golimumab | 50 mg q 4 weeks | ASAS20 response at week 16 | Placebo | ASAS20: 72% vs. 40% ASAS40: 57% vs. 23% |
AS Trials | |||||
ATLAS [56] | Adalimumab | 40 mg q 2 weeks | ASAS20 response at week 12 | Placebo | ASAS20: 58% vs. 21% ASAS40: 40% vs. 13% |
RAPID-axSpA (AS subset) [19] | Certolizumab pegol | 400 mg q 4 weeks | ASAS20 response at week 12 | Placebo | ASAS20: 64% vs. 37% ASAS40: 50% vs. 19% |
Etanercept phase III [57] | Etanercept | 50 mg q week | ASAS20 response at week 12 | Placebo | ASAS20: 59% vs. 28% ASAS50: 44% vs. 16% |
GO-RAISE [53] | Golimumab | 50 mg q 4 weeks | ASAS20 response at week 14 | Placebo | ASAS20: 59% vs. 22% ASAS40: 44% vs. 15% |